iifl-logo-icon 1

Phaarmasia Ltd Management Discussions

Jul 22, 2024|03:16:00 PM

Phaarmasia Ltd Share Price Management Discussions


India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. Globally, India ranks 3rd in terms of pharmaceutical production by volume a nd 1 4 th by value. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys a n important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers with a potential to steer the industry ahead to greater heights. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms.


Phaarmasia is committed to creating a better tomorrow. Phaarmasia believes in innovation. It provides state-of-the art prepositions to advance the companys relevance and foster a spirit of experimentation. Phaarmasia takes measurable risks in exploring new avenues of approach to business, applications and customer needs. During past a few decades, Phaarmasia has mastered and manufactured wide range of Pharmaceutical Formulations at a WHO-GMP certified and ISO 9001-certified manufacturing facility. Pharmaceutical products of Phaarmasia are consistent in term of quality and reliability. Phaarmasia is committed to creating a better tomorrow. Maintaining a core competency in Hormonal and steroidal products, allows us to maintain the right quality. We strive to manage this business in an ethical and transparent manner. In the never-ending quest for quality and better healthcare, we dedicate ourselves to exceed expectations of our customer and all our stakeholders as it provides us with the Competitive Edge. Our motto is to deliver to Our Customers with best quality products. “QUALITY” is the hallmark of Phaarmasia. We commit ourselves as a Company and as Individuals to ‘DO IT RIGHT FIRST TIME, EVERY TIME and to achieve this we have an environment that encourages our people, since ‘People makes the Difference. Maintaining a high level of respect within the industry and amongst professionals is important to us as this helps us in giving high quality products and services back to the society. The growth of Phaarmasia a s a n organization is the cumulative product of individual growth of our employees. Its the constant effort of all our employees working a s a wonderful team a s well a s motivated individuals that drives Phaarmasia to achieve bigger & better goals. Our intention is to aim at the development of innovative formulations and products. With the help of our dedicated team of researchers, we have produced various new innovative products with unmatched quality and are religious to continue our quest for the development of innovative dosage formulation. M/s Phaarmasia Limited (unit-I) is the part of the Maneesh Pharmaceutical limited, with its headquarters and marketing office in Mumbai. M/s Phaarmasia Limited Unit-II was established in 1993-94. Phaarmasia Limited is engaged in manufacturing and marketing of Oral contraceptive tablets" with various therapeutic dosage combinations along with iron tablets for Ministry of Health & Family Welfare and for Exports. The plant is situated in a hygienic environment; free from dust, smoke, chemical & biological emission. Phaarmasia Ltd. Is a n independent State-of-the-art-manufacturing unit having manufacturing facility of international standards with manufacturing capacity of more than 30 million units per annum.


Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medicine spending. Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers, which are on the rise. The Indian Government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies. Phaarmasia is trying its best to move ahead in planned manner to achieve the higher growth.


Company has recorded the revenue of Rs. 2,748.95 Lakhs during 2022-23 as compared to Rs. 1,721.58 Lakhs in 2021-22.

Other Incomes

The Other incomes for 2022-23 of Rs.51.61 Lakhs has decreased, compared to Rs. 46.97 Lakhs in 2021-22.


The expenses for 2022-23 of Rs. 2,943.77 Lakhs has reduced, compared to Rs. 1,924.76 Lakhs in 2021-22.

Profit before Tax

There is Loss before Tax for 2022-23 of Rs.143.20 Lakhs compared to Profit before Tax of Rs. 156.22 Lakhs in 2021-22.

Profits after Tax

The Loss After Tax for 2022-23 of Rs. 125.92 Lakhs as against Profit After Tax of Rs. 154.72 Lakhs in the previous year 2021-22.

Earnings per Share

The EPS for 2022-23 decreased to Rs.(1.84) as compared to Rs. (2.27) in Previous Year.


Risks are inherent to our business as our operating environment is complex, highly regulated, and dynamic. To attain our strategic growth objectives, protect the interests of all our stakeholders and meeting legal requirements we have an established process of identifying, analyzing, and responding appropriately to all business risks. We have a well-embedded Risk Management Framework to ensure that we are well-placed to manage any adverse effect posed by financial, operational, strategic or regulatory related risks. Our framework adopts appropriate risk mitigation measures for identified risks across functions. The process ensures that new risks, which might arise, or the impact of existing risks which might have increased, are identified and a strategy is put in place for mitigating such risks. The major risks identified by the management are regulatory, competition, supply chain disruption, cyber and data security.


Your Company has a robust and reliable system of internal controls commensurate with the nature of the business, and the scale and complexity of operations. The Company has adopted policies and procedures covering all financial, operating and compliance functions. These controls have been designed to provide a reasonable assurance over: 1. Effectiveness and efficiency of operations 2. Safeguarding of assets from unauthorised use or losses 3. Compliance with applicable laws and regulations 4. Prevention and detection of frauds and errors

5. Accuracy and completeness of the accounting records 6. Timely preparation of reliable financial information.

The current system of Internal Financial Controls (IFC) is aligned with the requirement of the Companies Act 2013, The Internal Audit (IA) function of the Company functionally reports to the Chairperson of the Audit Committee, thereby maintaining its objectivity.


Your Directors is focusing to strengths its Domestic Market through expansion of its activities and will make the necessary investment when attractive opportunities arise.


The pace at which the pharmaceutical sector in India is growing has increased the Opportunities for the company which can lead to healthy growth of the Company. The pharmaceutical sector is also exposed to various kinds of risks related to change in government policies, pricing of products, intense competition due to growth etc. The Company is well equipped to tackle the risks related to the business of the Company.


Your company has been following the philosophy of providing the highest quality products and services at the lowest possible prices. Your Companys philosophy to provide high class quality products i.e. full value for money, to consumers would greatly benefit in the long run. Your company will continue to follow this philosophy in the new operations that it is likely to undertake.


Phaarmasia Limited believes in creating an environment, wherein human resources derive a sense of purpose, passion and personal growth at work, leading to organizational performance. Towards realizing this, the company relies on the four pillars, namely, performance management, talent engagement, Capability development and maintaining cordial industrial relations. It also believes in review of its HR processes and systems on an ongoing basis to optimize costs, time and labour.


Statements in the Management Discussion and Analysis describing the Companys objective, projections, estimates, expectations may be forward-looking statements. Actual results may differ materially from those expressed or implied due to various risks and uncertainties. Important factors that could make a difference to the Companys operations include global a nd Indian demand-supply conditions, finished goods prices, changes in government regulations and policies, tax regimes, economic conditions within India and the countries within which the Company conducts business and other such factors. The Company does not undertake to update these statements.

Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.